University of Colorado - Eye Center
Welcome,         Profile    Billing    Logout  
 9 Trials 
17 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Cho, Steve
CLARIFY, NCT06056830: Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy

Recruiting
3
383
US, RoW
64Cu-SAR-bisPSMA
Clarity Pharmaceuticals Ltd
Prostate Cancer, Prostatic Neoplasms
02/25
02/25
NCI-2018-00466, NCT03302156: PSMA PET and MRI in Gynecological Cancers

Terminated
2
15
US
PSMA-based 18F-DCFPyL PET tracer, PSMA
University of Wisconsin, Madison
Gynecologic Cancer
01/20
01/20
NCT04573231: Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer

Recruiting
2
13
US
18F-DCFPyL
University of Wisconsin, Madison
Breast Cancer, HER2-negative Breast Cancer, Metastatic Breast Cancer
11/25
11/25
NCT05293626: Gene Therapy Clinical Trial for the Treatment of Leber's Hereditary Optic Neuropathy Associated With ND4 Mutations

Active, not recruiting
1/2
12
US
NR082 Injection, Injection needle, Syringe
Neurophth Therapeutics Inc
Leber Hereditary Optic Neuropathy (LHON)
07/25
12/29
NCT03232164: PSMA-based 18F-DCFPyL PET/CT and PET/MRI Pilot Studies in Prostate Cancer

Completed
1
126
US
18F-DCFPyL PET
University of Wisconsin, Madison
Prostate Cancer, Prostate Neoplasm
11/24
11/24
NCT06122610: Using Novel Imaging to More Safely Treat Neuroendocrine Tumors

Recruiting
1
10
US
Single Photon Emission Computed Tomography/ Computed Tomography (SPECT/CT), Photon Emission Tomography / CT (PET/CT), 64Cu-Dotatate, Detectnet, 177Lu-Dotatate, Lutathera®
University of Wisconsin, Madison
Neuroendocrine Tumors, Somatostatin Receptor-positive Neuroendocrine Tumor
04/25
04/25
NCT06199713: Correlating Early FDG PET/CT and ctDNA in Immune Checkpoint Inhibitor (ICI)-Treated Melanoma Patients

Recruiting
N/A
24
US
18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography, 18F-FDG PET/CT
University of Wisconsin, Madison
Melanoma, Melanoma Stage III, Melanoma Stage IV, Unresectable Melanoma
01/26
01/29
VENICE, NCT05280366: STREAMLINE®SURGICAL SYSTEM Compared to iStent Inject W® in Patients With Open-Angle Glaucoma

Active, not recruiting
N/A
150
US, RoW
Streamline Surgical System, iStent Inject W
New World Medical, Inc.
Open Angle Glaucoma
06/26
06/26
Preston, Mary
NCT05002998: TEPEZZA® (Teprotumumab-trbw) Post-Marketing Requirement Study

Active, not recruiting
4
313
Europe, US
Teprotumumab, TEPEZZA, Placebo, Saline Solution
Amgen
Thyroid Eye Disease
04/26
04/26
NCT04417530: Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma

Completed
2
22
US
AU-011, Suprachoroidal Microinjector, PDT Laser
Aura Biosciences
Uveal Melanoma, Ocular Melanoma, Choroidal Melanoma
04/24
04/24
NARROW, NCT05305079: NA-AION Risk Factors: New Perspectives

Completed
N/A
179
Europe, Canada, US, RoW
Rigshospitalet, Denmark, Velux Fonden, Fight for Sight, University of Copenhagen, Hamilton Health Sciences Corporation, Aarhus University Hospital, Aalborg University Hospital, Odense University Hospital, Farabi Eye Hospital, Wellington Hospital, University of Colorado, Denver, University of Utah, Lawson Health Research Institute, University of Sydney, Stanford University, Moorfields Eye Hospital NHS Foundation Trust, Massachusetts Eye and Ear Infirmary, University Hospital, Bordeaux, Synoptik-Fonden
Non-arteritic Ischemic Optic Neuropathy, Optic Disk Drusen
08/24
08/24
Subramanian, Prem
NCT05002998: TEPEZZA® (Teprotumumab-trbw) Post-Marketing Requirement Study

Active, not recruiting
4
313
Europe, US
Teprotumumab, TEPEZZA, Placebo, Saline Solution
Amgen
Thyroid Eye Disease
04/26
04/26
THRIVE, NCT05176639 / 2021-006794-37: A Safety, Tolerability and Efficacy Study of Veligrotug (VRDN 001) in Healthy Volunteers and Participants with Thyroid Eye Disease (TED) ( )

Active, not recruiting
3
154
Europe, Canada, US, RoW
Veligrotug (VRDN-001) Phase 1/2 MAD (HV and TED), VRDN-001 Phase 3 Cohort (THRIVE), VRDN-001 Placebo
Viridian Therapeutics, Inc., Viridian Therapeutics, Inc.
Thyroid Eye Disease
07/24
03/25
NCT05293626: Gene Therapy Clinical Trial for the Treatment of Leber's Hereditary Optic Neuropathy Associated With ND4 Mutations

Active, not recruiting
1/2
12
US
NR082 Injection, Injection needle, Syringe
Neurophth Therapeutics Inc
Leber Hereditary Optic Neuropathy (LHON)
07/25
12/29
NCT05820152: Gene Therapy Clinical Trial for the Treatment of Leber's Hereditary Optic Neuropathy Associated With ND1 Mutations

Terminated
1/2
11
US, RoW
NFS-02 Injection
Neurophth Therapeutics Inc
Leber Hereditary Optic Neuropathy (LHON)
06/24
06/24
NARROW, NCT05305079: NA-AION Risk Factors: New Perspectives

Completed
N/A
179
Europe, Canada, US, RoW
Rigshospitalet, Denmark, Velux Fonden, Fight for Sight, University of Copenhagen, Hamilton Health Sciences Corporation, Aarhus University Hospital, Aalborg University Hospital, Odense University Hospital, Farabi Eye Hospital, Wellington Hospital, University of Colorado, Denver, University of Utah, Lawson Health Research Institute, University of Sydney, Stanford University, Moorfields Eye Hospital NHS Foundation Trust, Massachusetts Eye and Ear Infirmary, University Hospital, Bordeaux, Synoptik-Fonden
Non-arteritic Ischemic Optic Neuropathy, Optic Disk Drusen
08/24
08/24
ACON, NCT05605951: Acute Optic Neuritis Network: an International Study That Invesitages Subjects With a First-ever Episode of Acute Inflammation of the Optic Nerve

Recruiting
N/A
200
Europe, Japan, US, RoW
non-interventional study
Experimental and Clinical Research Center, a cooperation between the Max Delbrück Center for Molecul
Demyelinating Diseases, Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorder Attack, Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease, Optic Neuritis
12/25
12/25

Download Options